These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7053283)

  • 21. Potentially serious interaction of warfarin with sulphinpyrazone.
    Thompson PL; Serjeant C
    Med J Aust; 1981 Jan; 1(1):41. PubMed ID: 7207296
    [No Abstract]   [Full Text] [Related]  

  • 22. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.
    Rindone JP; Keng HC
    Chest; 1998 Aug; 114(2):641-2. PubMed ID: 9726762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of warfarin-induced hypoprothrombinemia by triclofos.
    Sellers EM; Lang M; Koch-Weser J; Colman RW
    Clin Pharmacol Ther; 1972; 13(6):911-5. PubMed ID: 5081604
    [No Abstract]   [Full Text] [Related]  

  • 25. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate.
    Sellers EM; Koch-Weser J
    N Engl J Med; 1970 Oct; 283(16):827-31. PubMed ID: 5458032
    [No Abstract]   [Full Text] [Related]  

  • 26. Interaction of sulphinpyrazone with warfarin.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):327-31. PubMed ID: 7106169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.
    O'Reilly RA; Goulart DA; Kunze KL; Neal J; Gibaldi M; Eddy AC; Trager WF
    Clin Pharmacol Ther; 1992 Jun; 51(6):656-67. PubMed ID: 1611805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rabbit as an animal model for warfarin-induced hypoprothrombinemia: the relationship between prothrombin time and prothrombin complex activity.
    Nagata M; Yotsuyanagi T; Ikeda K
    Chem Pharm Bull (Tokyo); 1986 Feb; 34(2):813-8. PubMed ID: 3708732
    [No Abstract]   [Full Text] [Related]  

  • 29. Warfarin-sulfinpyrazone interaction on binding to human serum albumin.
    Larsen FG; Larsen CG; Brodersen R
    J Pharm Pharmacol; 1984 Oct; 36(10):689-90. PubMed ID: 6150088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis.
    Vagenakis AG; Cote R; Miller ME; Braverman LE; Stohlman F
    Johns Hopkins Med J; 1972 Jul; 131(1):69-73. PubMed ID: 4114451
    [No Abstract]   [Full Text] [Related]  

  • 31. Enhanced hypoprothrombinemia with warfarin due to azithromycin.
    Rao KB; Pallaki M; Tolbert SR; Hornick TR
    Ann Pharmacother; 2004 Jun; 38(6):982-5. PubMed ID: 15084685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.
    Bjornsson TD; Meffin PJ; Swezey S; Blaschke TF
    J Pharmacol Exp Ther; 1979 Sep; 210(3):316-21. PubMed ID: 480183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetics of coumarin anticoagulants XXIX: Elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration.
    Yacobi A; Levy G
    J Pharm Sci; 1977 Sep; 66(9):1275-7. PubMed ID: 903865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants.
    O'Reilly RA
    Am J Med Sci; 1979; 277(2):189-94. PubMed ID: 463946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin-induced hypoprothrombinemia. Potentiation by hyperthyroidism.
    Self T; Weisburst M; Wooten E; Straughn A; Oliver J
    JAMA; 1975 Mar; 231(11):1165-6. PubMed ID: 1172818
    [No Abstract]   [Full Text] [Related]  

  • 37. Prothrombin complex concentrates in acquired hypoprothrombinemia.
    Sandler SG; Rath CE; Ruder A
    Ann Intern Med; 1973 Oct; 79(4):485-91. PubMed ID: 4748270
    [No Abstract]   [Full Text] [Related]  

  • 38. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.
    Banfield C; O'Reilly R; Chan E; Rowland M
    Br J Clin Pharmacol; 1983 Dec; 16(6):669-75. PubMed ID: 6661352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy.
    O'Reilly RA
    Arch Intern Med; 1981 Mar; 141(4):458-9. PubMed ID: 7212888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.